Microbot Medical (MBOT) Price & Analysis

Compare

1,150 Followers

MBOT Stock Chart & Stats

$2.40

-$1.10(-38.87%)

At close: Jan 08 4:00 PM EST

$2.40

-$1.10(-38.87%)

Day’s Range― - ―

52-Week Range$0.93 - $4.67

Previous CloseN/A

Volume6.51M

Average Volume (3M)5.97M

Market Cap

$135.66M

Enterprise Value$0.00

Total Cash (Recent Filing)$80.16M

Total Debt (Recent Filing)$899.00K

Price to Earnings (P/E)―

Beta1.63

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.73

Shares Outstanding67,158,040

10 Day Avg. Volume3,110,764

30 Day Avg. Volume5,974,630

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)4.96

Price to Sales (P/S)0.00

P/FCF Ratio-1.98

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$8.75

Price Target Upside264.58% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Innovation And TechnologyLIBERTY is the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, indicating a significant innovation in medical technology.

Market AdoptionEmory University Hospital becomes the first hospital to adopt the LIBERTY endovascular robotic system, marking a significant commercial milestone.

Regulatory ApprovalThe LIBERTY endovascular robotic system achieved FDA clearance and has begun commercial use in select US hospitals.

Bears Say

Commercialization RisksRisks to achieving the price target include delays in commercialization, inability to expand into cardio and neuro cases, and lack of profitability in the near term.

Financial RisksRisks include slower than anticipated commercial uptake due to market size, penetration rate, and/or competition, and potential dilution risk.

Market PenetrationRisks include slower than anticipated commercial uptake due to market size, penetration rate, and/or competition.

Microbot Medical News

Microbot Medical initiated with a Buy at Roth Capital

Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical (MBOT) with a Buy rating and $5.50 price...

9d ago

MBOT

Microbot Medical announces Emory University first hospital to adopt LIBERTY

Microbot Medical (MBOT) announced that Emory University Hospital, a nationally recognized academic medical center in Atlanta, has become...

16d ago

MBOT

Microbot Medical’s LIBERTY System Gains Momentum with Emory University Adoption and Strategic Market Release

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Microbot Medical, retaining the price target of...

14d ago

MBOT

Microbot Medical Partners with Emory for Robotics Program

Microbot Medical ( ($MBOT) ) has shared an announcement. On November 26, 2025, Microbot Medical announced that Emory...

16d ago

MBOT

Microbot Medical’s Strategic Positioning and Growth Prospects Justify Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Microbot Medical. The associated price target...

21d ago

MBOT

Microbot Medical Launches LIBERTY® System in U.S.

Microbot Medical ( ($MBOT) ) has issued an announcement. On November 5, 2025, Microbot Medical announced the limited...

1M ago

MBOT

Microbot Medical commences LMR of its LIBERTY system in the U.S.

Microbot Medical (MBOT) announced that its LIBERTY System, the first FDA cleared single-use, remotely operated robotic system for...

1M ago

MBOT

Microbot Medical Showcases LIBERTY® System Post-FDA Clearance

Microbot Medical ( ($MBOT) ) just unveiled an update. On October 16, 2025, Microbot Medical announced its participation...

2M ago

MBOT

Microbot Medical to commercially debut LIBERTY System at Symposium

Microbot Medical (MBOT) announced that it will be exhibiting the LIBERTY System at the upcoming Symposium on Clinical...

2M ago

MBOT

Microbot Medical Partners for LIBERTY System Launch

An update from Microbot Medical ( ($MBOT) ) is now available. On October 14, 2025, Microbot Medical announced...

2M ago

MBOT

Microbot Medical partners with 3PL company to commercialize LIBERTY System

Microbot Medical (MBOT) has partnered with a U.S. based third-party logistics, 3PL, company to support the commercialization of...

2M ago

MBOT

Microbot Medical files to sell 900,153 shares of common stock for holders

06:31 EDT Microbot Medical (MBOT) files to sell 900,153 shares of common stock for holders Published first on...

2M ago

MBOT

Microbot Medical files to sell 14.69M shares of common stock for holders

06:31 EDT Microbot Medical (MBOT) files to sell 14.69M shares of common stock for holders Published first on...

2M ago

MBOT

Microbot Medical Completes Final Closing of Investment Options

An update from Microbot Medical ( ($MBOT) ) is now available. On October 6, 2025, Microbot Medical Inc....

2M ago

MBOT

MBOT FAQ

What was Microbot Medical Inc’s price range in the past 12 months?

Microbot Medical Inc lowest stock price was $0.93 and its highest was $4.67 in the past 12 months.

What is Microbot Medical Inc’s market cap?

Microbot Medical Inc’s market cap is $135.66M.

When is Microbot Medical Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Microbot Medical Inc’s earnings last quarter?

Currently, no data Available

Is Microbot Medical Inc overvalued?

According to Wall Street analysts Microbot Medical Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Microbot Medical Inc pay dividends?

Microbot Medical Inc does not currently pay dividends.

What is Microbot Medical Inc’s EPS estimate?

Microbot Medical Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Microbot Medical Inc have?

Microbot Medical Inc has 67,158,040 shares outstanding.

What happened to Microbot Medical Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Microbot Medical Inc?

Currently, no hedge funds are holding shares in MBOT

Microbot Medical Stock Smart Score

Neutral

Fundamentals

Return on Equity

-69.80%

Trailing 12-Months

Asset Growth

345.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

MBOT Stock 12 Month Forecast

Average Price Target

$8.75

▲(264.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,3.009230769230769,3.758461538461538,4.507692307692308,5.256923076923076,6.006153846153846,6.7553846153846155,7.504615384615384,8.253846153846155,9.003076923076923,9.752307692307692,10.50153846153846,11.250769230769231,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.759230769230769,3.258461538461538,3.7576923076923077,4.256923076923076,4.756153846153846,5.2553846153846155,5.754615384615384,6.253846153846154,6.753076923076923,7.252307692307692,7.751538461538462,8.250769230769231,{"y":8.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.26,2.509230769230769,2.758461538461538,3.0076923076923077,3.256923076923077,3.506153846153846,3.7553846153846155,4.004615384615384,4.253846153846154,4.503076923076923,4.752307692307692,5.001538461538462,5.250769230769231,{"y":5.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.43,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >